GSTM1 and anemia: Hb cycling has been linked to adverse outcomes and substantially increases the cost of anemia management, underscoring the need for safer and more consistent treatment strategies (Fishbane and Berns, 2007; Collins et al., 2012; Boudville et al., 2009; Swaminathan et al., 2015).